Barclays PLC Grows Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Barclays PLC boosted its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 1,316.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 140,113 shares of the company’s stock after buying an additional 130,219 shares during the period. Barclays PLC’s holdings in GoodRx were worth $973,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. American Century Companies Inc. purchased a new position in shares of GoodRx in the 2nd quarter valued at $18,183,000. Plato Investment Management Ltd acquired a new stake in GoodRx in the 2nd quarter valued at $43,000. XTX Topco Ltd lifted its stake in shares of GoodRx by 42.4% during the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after purchasing an additional 8,801 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in shares of GoodRx by 5.9% in the second quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock valued at $1,296,000 after buying an additional 9,200 shares in the last quarter. Finally, Rubric Capital Management LP grew its stake in shares of GoodRx by 76.5% in the second quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock valued at $29,147,000 after buying an additional 1,619,748 shares in the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GDRX shares. Mizuho started coverage on GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target on the stock. Morgan Stanley reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. KeyCorp lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Citigroup cut their price objective on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Friday, January 10th. Finally, Barclays lowered their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, GoodRx currently has an average rating of “Moderate Buy” and a consensus price target of $8.38.

GoodRx Trading Down 1.7 %

Shares of NASDAQ GDRX opened at $4.15 on Wednesday. The stock has a market capitalization of $1.58 billion, a P/E ratio of -138.33, a PEG ratio of 3.43 and a beta of 1.27. The stock’s 50 day moving average price is $4.65 and its two-hundred day moving average price is $6.50. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 52-week low of $4.09 and a 52-week high of $9.26.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.